866-997-4948(US-Canada Toll Free)

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 53 Pages


Global Markets Directs, \'Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL). 

Refractory Chronic Lymphocytic Leukemia (CLL) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Refractory Chronic Lymphocytic Leukemia (CLL).
  • A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Refractory Chronic Lymphocytic Leukemia (CLL) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) 7
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Development by Companies 9
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Development by Companies 14
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Development 16
Santaris Pharma A/S 16
Pharmacyclics, Inc. 17
Memgen, LLC. 18
SBI Biotech Co., Ltd. 19
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
navitoclax - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ibrutinib - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SPC-2996 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISF-35 + [cyclophosphamide] + [fludarabine phosphate] - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 35
GNKG-168 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
navitoclax + [cyclophosphamide] + [fludarabine] + [rituximab] - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ABT-199 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Drug Profile Updates 42
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products 48
Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 49
Featured News & Press Releases 49
Aug 01, 2012: Pharmacyclics To Receive $50m Milestone Payment From Janssen Biotech 49
Jun 16, 2012: Pharmacyclics Announces Updated Results For Ibrutinib Combination Study At European Hematology Association Annual Congress 49
Jun 01, 2009: Trubion Announces Positive Data From A Phase I / II Study Of TRU-016 For The Treatment Of Chronic Lymphocytic Leukemia (CLL) 50

Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Table


Number of Products Under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2013 7
Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Santaris Pharma A/S, H1 2013 16
Pharmacyclics, Inc., H1 2013 17
Memgen, LLC., H1 2013 18
SBI Biotech Co., Ltd., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Combination Products, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 25
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Drug Profile Updates 42
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Dormant Products 48

List of Chart


Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2013 7
Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 20
Assessment by Combination Products, H1 2013 21
Assessment by Route of Administration, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Molecule Type, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *